DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
Recognized for Advancing Global Wound Care Through Innovation and Efficacy
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, the flagship product of DEBx Medical has been awarded the
IIWCG Achievement Award 2025
for
Innovation in Wound Care
at the
16th Abu Dhabi Wound Care Conference
.
Media Snippet
.
Presented during the Opening Ceremony at ADNEC, this recognition by the
International Interprofessional Wound Care Group (IIWCG)
honors excellence in wound care and spotlights breakthroughs redefining standards in chronic wound management through innovation and efficacy.
It is not only an honor for DEBx Medical—it's a tribute to the clinical judgment of many clinicians who continue to put DEBRICHEM® into practice and improve outcomes, even in the most challenging cases.
DEBRICHEM®: One Application. First Line. Debridement Solution.
With just one
60-second
application, DEBRICHEM® eradicates devitalized tissue, infection, and biofilm from chronic wounds, key barriers that prevent healing from progressing.
For clinicians, it offers
:
Rapid, targeted action, reopening the pathway to healing
An easy-to-use approach for multifactorial wounds
A results-driven practical solution in high-pressure settings
For healthcare systems and patients, it enables
:
Fewer interventions and lower resource use
Better patient compliance across different wound etiologies
Potential reduced reliance on antibiotics, helping to counter antimicrobial resistance
A meaningful step forward in the fight against amputations
Backed by scientific evidence, DEBRICHEM® supports clinicians in both advanced hospital settings and remote or resource-limited environments.
In a time when healthcare efficiency and antimicrobial resistance are pressing global concerns, innovation like DEBRICHEM® is not just valuable, it's vital.
'It's a moment of shared pride and purpose. This recognition by the IIWCG is an incredible honor, not just for DEBx Medical, but for every clinician and patient who places their trust in innovation. DEBRICHEM® was developed to meet a critical gap in chronic wound care. This award validates the real-world impact our team strives for every day: restoring dignity, preserving limbs, improving lives.'—
Bert Quint, CEO, DEBx Medical
The award underscores DEBx Medical's commitment to advancing wound care that prioritizes patient progress above all.
About DEBx Medical
DEBx Medical is a medical technology business dedicated to revolutionizing the management of chronic wounds. It focuses on delivering disruptive and efficient wound care treatments that are easy to use and implement in daily clinical practice:
DEBRICHEM® – Innovating The Future of Wound Care
For inquiries:
DEBx Medical
: Chandrita Jaisinghani,
[email protected]
, +31 85 0878096
GlobeNewswire Distribution ID 1001093124
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bahrain News Gazette
08-05-2025
- Bahrain News Gazette
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2025 Earnings Call Webcast . For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah's Q1 2025 Earnings Call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study. For more information, please visit . Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States FORWARD-LOOKING STATEMENTS Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio® system; receipt of FDA approval; satisfactory completion of a manufacturing facilities, methods and controls review, and the anticipated timing of the foregoing; entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: Nyxoah John Landry, CFO [email protected] For Media In United States FINN Partners – Alyssa Paldo [email protected] In International/Germany MC Services – Anne Hennecke [email protected] In Belgium/France Backstage Communication – Gunther De Backer [email protected] Attachment ENGLISH_Q1 Earnings Call Announcement_FINAL GlobeNewswire Distribution ID 1001095238
Bahrain News Gazette
08-05-2025
- Bahrain News Gazette
EAACI Hong Kong Allergy School 2025: A Landmark in Global Allergy Education
ZURICH, May 08, 2025 (GLOBE NEWSWIRE) — The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong Kong Allergy School. This significant milestone will unfold in Hong Kong – Asia's World City – a dynamic hub where East meets West, innovation meets tradition, and global minds converge. Under the theme 'East Meets West', the 2025 edition of the Allergy School represents a bold step in fostering cross-continental collaboration in allergy and clinical immunology. By bringing together leading global experts, this flagship event aims to enrich knowledge exchange, advance clinical practices, and inspire innovative solutions to allergy care worldwide. Participants will benefit from a rich, interdisciplinary scientific programme, featuring renowned international faculty and cutting-edge topics across the allergy and immunology spectrum. A special dedicated Chinese-language track will be available, promoting inclusivity and greater accessibility for Chinese-speaking professionals. Attendees will also present their research through oral and poster sessions, connect with industry leaders, and build lasting collaborations within the global allergy community. Prizes will be awarded to top abstracts as selected by EAACI's international panel of experts. In celebration of this milestone, EAACI is offering exclusive benefits: Discounted registration for current EAACI members A complimentary 1-year EAACI membership for registered delegates that are not EAACI members We invite you to submit your abstracts and take advantage of early bird registration, available now. The abstract submission deadline is 31 st May 2025. As we gather to celebrate innovation, partnership, and progress, we also invite you to experience the vibrant city of Hong Kong – its iconic skyline, diverse cuisine, and cultural richness – the perfect setting for this global exchange. Join us in shaping the future of allergy science and care. Your participation will help build a thriving; interconnected network of professionals dedicated to better outcomes for patients everywhere. Explore the programme, register, and plan your visit at: About EAACI The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization dedicated to excellence in allergy and immunology. Learn more at . Contact: [email protected] +41 44 205 55 33 GlobeNewswire Distribution ID 1001095348
Trade Arabia
01-05-2025
- Trade Arabia
Novo Nordisk, Ebn Sina Medical launch Wegovy in Qatar
Ebn Sina Medical, a subsidiary of Aamal Company and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish global healthcare company, have announced the availability of Wegovy (Semaglutide 2.4mg) in Qatar. The event was attended by Anders Bjørn Hansen, the Ambassador of Denmark to the UAE and Qatar, Aamal Company CEO Rashid Al Mansoori, Manvendra Singh, General Manager of Novo Nordisk Qatar and Dr Nayla Mansour, Commercial Director of Ebn Sina Medical. Wegovy® (Semaglutide 2.4mg), the once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above, is now available in Qatar. Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide. Obesity in the Gulf is rapidly unfolding with the highest rates globally. In Qatar, the obesity crisis is particularly severe, the current prevalence of obesity (body mass index [BMI] ≥ 30 kg/m2) amongst adults in Qatar is estimated to be 41% with a notably higher prevalence amongst women (46%) and, nearly 76% of individuals in Qatar are classified as overweight. This places Qatar among the top 10 highest obesity rates in the world, a statement said quoting statisitics. The high rates of obesity and overweight in Qatar are linked to the high-country overall rates of related chronic conditions such as pre-diabetes, diabetes and cardiovascular diseases (CVDs). The active ingredient in Wegovy®, Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness. Wegovy is indicated as adjunct to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m2) or with overweight (BMI ≥ 27 kg/m2) in the presence of at least one weight-related comorbidity. As per clinical research, Wegovy on top of diet and exercise delivers 17% mean weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss. Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, Glycemic parameters & C-reactive protein, the statement said. The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Semaglutide 2.4 mg resulted in a statistically significant 20% risk reduction in Major Adverse Cardiovascular Events (MACE) in people with overweight or obesity and established CVD, without T2DM1, it said. Besides its indication in adults, Wegovy® is also approved as the first and only once weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management in adolescents with obesity from the age of 12 years. This innovation may help transform the medical management of adolescent obesity in Qatar, where nearly 20% of children and adolescents are affected, it noted. - TradeArabia News Service
